Women not receiving risedronate in stratum I and II who received anastrozole ( @ women ) had a significant BMD decrease after @ years of follow-up compared with women who received placebo ( @ women ) at the lumbar spine ( -@ % -LSB- -@ to -@ -RSB- vs -@ % -LSB- -@ to -@ -RSB- , p < @ ) and total hip ( -@ % -LSB- -@ to -@ -RSB- vs -@ % -LSB- -@ to -@ -RSB- , p < @ ) .